Abstract
Since the association of circulating DNA level changes with tumor growth was discovered many attempts have been made to develop the sensitive and robust blood-based tests for early tumor diagnostics. Both genomic as well as mitochondrial DNA quantification in the circulation have been extensively evaluated as a diagnostic and prognostic tool to monitor cancer therapy. Cell-free DNA bearing the same genetic and epigenetic changes as the tumor tissues were shown to be detectable in plasma / serum of cancer patients indicating the principal possibility to create the minimally invasive diagnostic tests based on tumor-specific DNA markers. Apart from circulating DNA, tumor-derived RNA in plasma / serum was found to be a promising approach for the development of cancer markers. Results of the last two years establish the quantification of the tumor-derived microRNAs in plasma / serum as an extremely promising approach for cancer diagnostics. The aim of this publication was to review the recently reported studies on the circulating DNA and RNA in cancer patients and to estimate their impact on making the ongoing research closer to clinical application.
Keywords: Circulating DNA, RNA, cancer, diagnostics, genetic mutations, allelic imbalance, gene methylation, microRNA
Current Molecular Medicine
Title: Circulating Nucleic Acids as a Potential Source for Cancer Biomarkers
Volume: 10 Issue: 2
Author(s): V. V. Vlassov, P. P. Laktionov and E. Y. Rykova
Affiliation:
Keywords: Circulating DNA, RNA, cancer, diagnostics, genetic mutations, allelic imbalance, gene methylation, microRNA
Abstract: Since the association of circulating DNA level changes with tumor growth was discovered many attempts have been made to develop the sensitive and robust blood-based tests for early tumor diagnostics. Both genomic as well as mitochondrial DNA quantification in the circulation have been extensively evaluated as a diagnostic and prognostic tool to monitor cancer therapy. Cell-free DNA bearing the same genetic and epigenetic changes as the tumor tissues were shown to be detectable in plasma / serum of cancer patients indicating the principal possibility to create the minimally invasive diagnostic tests based on tumor-specific DNA markers. Apart from circulating DNA, tumor-derived RNA in plasma / serum was found to be a promising approach for the development of cancer markers. Results of the last two years establish the quantification of the tumor-derived microRNAs in plasma / serum as an extremely promising approach for cancer diagnostics. The aim of this publication was to review the recently reported studies on the circulating DNA and RNA in cancer patients and to estimate their impact on making the ongoing research closer to clinical application.
Export Options
About this article
Cite this article as:
Vlassov V. V., Laktionov P. P. and Rykova Y. E., Circulating Nucleic Acids as a Potential Source for Cancer Biomarkers, Current Molecular Medicine 2010; 10 (2) . https://dx.doi.org/10.2174/156652410790963295
DOI https://dx.doi.org/10.2174/156652410790963295 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
TGF-beta Signaling in Cancer Treatment
Current Pharmaceutical Design Dietary Habits of Mongolian People, and Their Influence on Lifestyle-Related Diseases and Early Aging
Current Aging Science Repulsive Guidance Molecules (RGMs) and Their Potential Implication in Cancer as Co-receptor of BMPs
Current Signal Transduction Therapy Long Term Complications in Pediatric Liver Transplant Recipients: What Every Pediatrician Should Know
Current Pediatric Reviews HDL Genetic Defects
Current Pharmaceutical Design From HPV Infection to Oncogenesis: A Brief Review of the Complex Immunobiological Events
Current Cancer Therapy Reviews Physiological Functions of Presenilins; Beyond γ-Secretase
Current Pharmaceutical Biotechnology Long Term Cardiovascular Risk in Women
Vascular Disease Prevention (Discontinued) Targeted Therapy of the Insulin-Like Growth Factor-1 Receptor in Cancer
Combinatorial Chemistry & High Throughput Screening Localization Patterns of Sumoylation Enzymes E1, E2 and E3 in Ocular Cell Lines Predict Their Functional Importance
Current Molecular Medicine Lung Defence Mechanisms and Their Potential Role in the Prevention of Ventilator Associated Pneumonia
Current Respiratory Medicine Reviews Vascular Injury During Elevated Glucose can be Mitigated by Erythropoietin and Wnt Signaling
Current Neurovascular Research Synthetic Strategies Towards O6-Substituted Guanine Derivatives and their Application in Medicine
Current Organic Synthesis Optimal Sequencing of New Drugs in Metastatic Castration-Resistant Prostate Cancer: Dream or Reality?
Current Drug Targets Editorial [Hot Topic: Angiogenesis in Tumor Growth and Metastasis (Executive Editor: Riichiro Abe)]
Current Pharmaceutical Design Sodium Selenite as an Anticancer Agent
Anti-Cancer Agents in Medicinal Chemistry In-vitro Pre-Treatment of Cancer Cells with TGF-β1: A Novel Approach of Tail Vein Lung Cancer Metastasis Mouse Model for Anti-Metastatic Studies
Current Molecular Pharmacology Oxidative Stress and Cancer: The Role of Nrf2
Current Cancer Drug Targets Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery PARG Inhibitors and Functional PARG Inhibition Models
Current Protein & Peptide Science